Built from science.
Driven by purpose.
We translate microbiome complexity into clinically validated solutions for metabolic health.
We translate microbiome complexity into clinically validated solutions for metabolic health.
Postbiotics overcome many of these limitations. As inactivated microbial preparations, they can offer greater stability, consistency and compatibility with food, beverages and supplement manufacturing.
This makes them especially relevant for food, beverage and nutraceutical applications where stability, consistency and formulation flexibility are essential.
Metabolic health depends on complex interactions between nutrition, gut microbiota and host biology. Genbioma was created with the aim of better understanding those interactions and translate them into practical solutions.
Our mission is to develop clinically validated microbiome-based ingredients that support metabolic balance through safe, stable and reproducible formats.
By combining proprietary strain research, in vivo validation, human studies and collaboration with clinical and academic partners, we aim to advance a new generation of postbiotic solutions for metabolic health.
The gut microbiome is a highly complex biological system. Understanding how it influences metabolic balance requires the integration of microbiology, data science, in vivo models, multi-omics analysis and human validation.
Genbioma has developed a proprietary technology platform to identify, characterize and validate bacterial strains and postbiotic solutions with potential applications in metabolic health. Our approach combines advanced screening, mechanistic analysis and clinical evidence to select candidates with a clear biological rationale and a strong path toward industrial development.
We build our science around three principles:
Selecting candidates based on their potential to modulate key metabolic pathways.
Validating activity through preclinical models, human studies and real-world evidence.
Developing postbiotic formats designed for stability, scalability and formulation compatibility.
The result is a rigorous development process that connects microbiome research with clinically validated, industry-ready postbiotic solutions.
Genbioma was founded in 2019 by a team combining academic expertise, food innovation experience and a proven track record in microbiome-based product development.
The company was born from the convergence of two complementary strengths: academic research from the Public University of Navarra and entrepreneurial experience in the development of microbiome-based products, including the legacy of Pentabiol in probiotic innovation.
From the beginning, Genbioma focused on a clear objective: identifying specific bacterial strains with metabolic potential and transforming them into safe, stable and clinically validated postbiotic ingredients.
Today, that work has evolved into a growing portfolio of microbiome-based solutions, starting with pA1c®HI, our leading postbiotic ingredient for metabolic health applications.
Premio EmprendeXXI Startup más innovadora en NAVARRA 2023
“Healthy Food” Award at FoodTech Innovation Awards, Food 4 Future ExpoFoodTech 2024
Spain UP Nation’s Top 101 2024
Food for Health Challenge 2024
Premio EmprendeXXI Startup más innovadora en NAVARRA 2023
“Healthy Food” Award at FoodTech Innovation Awards, Food 4 Future ExpoFoodTech 2024
Sello Pyme Innovadora 2022
Probiota Pioneers 2022
APTENISA 2022
EIT FUN&FAN AWARD 2021
2024 – 2025
Ayudas para la creación y consolidación de empresas innovadoras de base tecnológica (EIBT) 2025
As part of its ongoing commitment to innovation, Genbioma has launched a new R&D initiative supported by the Government of Navarra. This strategic project aims to accelerate the development of advanced postbiotic solutions to improve metabolic health, with a focus on type 2 diabetes, prediabetes, and obesity.
Esta empresa ha recibido una subvención del Gobierno de Navarra al amparo de la convocatoria de 2025 de ayudas a la creación y consolidación de empresas innovadoras de base tecnológica en el marco del Plan deRecuperación, Transformación y Resiliencia – Financiado por la Unión Europea – Next Generation EU.
2024 – 2025
Ayudas para la creación y consolidación de empresas innovadoras de base tecnológica (EIBT) 2025
As part of its ongoing commitment to innovation, Genbioma has launched a new R&D initiative supported by the Government of Navarra. This strategic project aims to accelerate the development of advanced postbiotic solutions to improve metabolic health, with a focus on type 2 diabetes, prediabetes, and obesity.
Esta empresa ha recibido una subvención del Gobierno de Navarra al amparo de la convocatoria de 2025 de ayudas a la creación y consolidación de empresas innovadoras de base tecnológica en el marco del Plan deRecuperación, Transformación y Resiliencia – Financiado por la Unión Europea – Next Generation EU.
2022 – 2025
PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2021
Precision Medicine Against Type 2 Diabetes: Genetic Prediction and Nutritional Intervention with Probiotics Modulating the Microbiota
Genbioma launches the CPP2021-008725 project, titled “.” This innovative project, funded by the Ministry of Science and Innovation and the European Union through the Next Generation EU funds, aims to develop advanced solutions for managing Type 2 diabetes.
By leveraging genetic prediction and nutritional interventions with probiotics, Genbioma seeks to improve patient outcomes and contribute to the field of precision medicine. The project is a collaborative effort involving Genbioma, the Biocruces Bizkaia Health Research Institute, the University of Navarra, and Patia. The total funding for this project is €1,700,000.
2022 -2023
The NEOTEC 2021 project is centered on advancing business development and formulating a comprehensive strategic business plan. This initiative is supported by a grant of 325,000 € from CDTI and is co-financed by the European Union through the Next Generation EU funds.The project aims to enhance Genbioma’s market presence by identifying new business opportunities and optimizing its operational strategies. It focuses on scaling up the production of their innovative postbiotic ingredients, expanding their market reach, and establishing strategic partnerships. Additionally, the project includes the development of a robust marketing strategy to promote their products and increase brand awareness. This comprehensive approach is designed to ensure sustainable growth and long-term success for Genbioma in the competitive biotechnology sector.
2023
Programa EUROPA + CERCA 2023
Genbioma Aplicaciones SL receives aid from the call “PROGRAMA EUROPA + CERCA 2023.” This aid aims to provide subsidies for the participation in European projects. The initiative seeks to strengthen the capacity of organizations to engage in European projects by facilitating the incorporation of specialized personnel and resources. Funded by the Government of Navarra.
2023
Ayudas a la contratación de personas promotoras y gestoras de proyectos europeos 2023
Aid from the call “Grants for the hiring of promoters and managers of European projects” for the year 2023. This aid aims to provide subsidies for the hiring of individuals who will promote and manage European projects. The initiative seeks to strengthen the capacity of organizations to participate in European projects by facilitating the incorporation of specialized personnel in the promotion and management of such projects. The aid is provided by the Government of Navarra and amounts to 15.000 €.
2021-2022
TRANSFERENCIA CONOCIMIENTO GOBIERNO DE NAVARRA 2020
Funded by the Government of Navarra under the Knowledge Transfer program. This project has received a grant of €416,000 and is co-financed by the European Regional Development Fund (ERDF) through the 2021-2027 Operational Program of Navarra.
The project aims to develop nutritional formulas for prediabetic populations based on microorganisms with normoglycemic capabilities. The goal is to create a new nutritional supplement incorporating a bacterial strain with a differential normoglycemic effect, targeting prediabetic individuals. The project is a collaboration between Genbioma Aplicaciones SL, UPNA, and CIN-UNAV.